Related Experiment Video
Updated: May 14, 2026

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
Published on: June 18, 2020
Antineutrophil cytoplasm antibody-associated vasculitis: recent developments.
Shunsuke Furuta1, David R W Jayne
1Lupus and Vasculitis Clinic, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK. shunsuke.furuta@addenbrookes.nhs.uk
Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is an autoimmune disease. Recent research shows genetic and environmental factors contribute to AAV, with new treatments like rituximab offering improved outcomes.
Area of Science:
- Rheumatology
- Immunology
- Genetics
Background:
- Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) involves small-to-medium vessel inflammation.
- The autoimmune basis of AAV is increasingly recognized, though causes remain incompletely understood.
Purpose of the Study:
- To review recent advancements in the etiology, pathogenesis, classification, and treatment of AAV.
- To highlight new findings in genetic susceptibility, environmental triggers, and diagnostic markers for AAV.
Main Methods:
- Review of recent literature and clinical data.
- Analysis of genome-wide association studies and international consensus initiatives.
- Detection of novel autoantibodies in AAV patient sera.
Main Results:
- Genetic susceptibility and environmental factors (e.g., neutrophil extracellular traps) are implicated in AAV.
- Revised classification of vasculitis and prognostic renal biopsy classification developed.
- Rituximab identified as an alternative to cyclophosphamide for remission induction in AAV.
Conclusions:
- AAV has a significant autoimmune component influenced by genetic and environmental factors.
- Updated classification and novel autoantibodies aid in AAV diagnosis and prognosis.
- Rituximab offers an effective treatment option, but long-term risks like cardiovascular and malignant diseases require monitoring.
More Related Videos
11:32Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists
Published on: October 18, 2024
09:59A High-throughput Assay to Assess and Quantify Neutrophil Extracellular Trap Formation
Published on: January 29, 2019
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Pyelonephritis I: Introduction
Nephrotic Syndrome I : Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Nephrotic Syndrome II : Assessment and Medical Management